Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immunome, Inc. before investing.

In this article, we go over a few key elements for understanding Immunome, Inc.’s stock price such as:

• Immunome, Inc.’s current stock price and volume
• Why Immunome, Inc.’s stock price changed recently
• Upgrades and downgrades for IMNM from analysts
• IMNM’s stock price momentum as measured by its relative strength

About Immunome, Inc. (IMNM)

Before we jump into Immunome, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Want to learn more about Immunome, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immunome, Inc..

What Caused Immunome, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 29, 2026, there were 0 analysts who downgraded Immunome, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Immunome, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immunome, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Immunome, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immunome, Inc. (IMNM) by visiting AAII Stock Evaluator.

Relative Price Strength of Immunome, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 29, 2026, Immunome, Inc. has a weighted four-quarter relative price strength of 15.33%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Immunome, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immunome, Inc. Stock Price: Bottom Line

As of June 1, 2026, Immunome, Inc.’s stock price is $21.175, which is down 3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immunome, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.